Drug Profile
Synthetic cannabidiol - Benuvia Therapeutics/Radius Health
Alternative Names: Pharmaceutical cannabidiol (CBD) - Benuvia Therapeutics/Radius Health; RAD-011Latest Information Update: 12 Dec 2022
Price :
$50
*
At a glance
- Originator INSYS Therapeutics, Inc
- Developer Benuvia Therapeutics; California Pacific Medical Center; INSYS Therapeutics, Inc; Radius Health Inc.; The University of Montreal Hospital Research Center; University of Chicago
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Prader-Willi syndrome
- Preclinical Endocrine disorders
- Discontinued Dravet syndrome; Epilepsy; Glioblastoma; Infantile spasms; Lennox-Gastaut syndrome; Pain; Peripheral nervous system diseases; Substance-related disorders
Most Recent Events
- 07 Dec 2022 Radius Pharmaceuticals terminates phase-II/III clinical trials in Prader-Willi syndrome (In adolescents, In children, In the elderly, In adults) in US, Spain and Sweden due to change in corporate priorities (PO) (NCT05098509)
- 06 Oct 2022 Radius Pharmaceuticals withdraws prior to enrollment a phase III trial for Prader-Willi Syndrome (In adolescents, In adults, In children, In the elderly) (PO) (NCT05387798)
- 22 Aug 2022 Radius Health plans a phase III trial for Angelman syndrome in USA (PO) in Q4 of 2022 (Radius Health pipeline, August 2022)